Texas Southern University, College of Pharmacy and Health Sciences, Houston, Texas.
Sr Care Pharm. 2021 Nov 1;36(11):548-555. doi: 10.4140/TCP.n.2021.548.
Glucagonlike peptide-1 receptor agonist is a common antidiabetic medication class to lower HbA1c, weight, and cardiovascular risk. This case study describes the challenges a patient with uncontrolled diabetes faced after receiving a prescription for liraglutide because of multiple levels of influence, including individual, family, institutional, and policy level barriers. The case highlights the importance of utilizing a person-centered care approach by evaluating patient's preferences, visual and motor coordination, cognitive function, psychological stress, and medication cost before prescribing injectable products for elderly patients.
胰高血糖素样肽-1 受体激动剂是一种常见的降糖药物,可降低 HbA1c、体重和心血管风险。本病例研究描述了一位糖尿病控制不佳的患者在接受利拉鲁肽处方后面临的挑战,这涉及多个层面的影响,包括个人、家庭、机构和政策层面的障碍。该病例强调了在为老年患者开处注射用产品前,评估患者的偏好、视觉和运动协调能力、认知功能、心理压力和药物费用的重要性,采用以人为本的护理方法。